Form 4: Ligand Pharmaceuticals Director Stephen Sabba Reports Share Acquisition and Option Exercise
SEC Form 4 Filing
Director Stephen Sabba reports acquisition of common stock and exercise of non-qualified stock options in Ligand Pharmaceuticals.
Summary
- Stephen L. Sabba, a director of Ligand Pharmaceuticals, reported a transaction involving the acquisition of 2,406 shares of common stock on April 1, 2025, at a price of $52.30.
- This acquisition was related to the exercise of non-qualified stock options.
- Following the reported transaction, Sabba directly owns 32,584 shares of common stock.
- The exercise of the shares was previously disclosed on Form 144 filed on March 17, 2025.
- The filing of this Form 4 was delayed due to inadvertent oversight.
Sentiment
Score: 6
Explanation: Neutral sentiment as it primarily reports a routine transaction. The delayed filing is a minor negative, but the explanation mitigates concern.
Negatives
- The filing of this Form 4 was delayed due to inadvertent oversight.
Risks
- The delayed filing of the Form 4, although attributed to inadvertent oversight, could raise concerns about compliance with SEC regulations.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| June 14, 2024 | Date of the Annual Meeting where 1,252 restricted shares were approved by the Board of Directors. |
| June 25, 2024 | Date of Reporting Person's Form 4, which was filed to reflect the 2024 Meeting grant. |
| March 17, 2025 | Date of Reporting Person's Form 144, which disclosed the proposed exercise of shares. |
| April 01, 2025 | Date of transaction: acquisition of 2,406 shares of common stock through option exercise. |
| April 16, 2025 | Date of signature on the Form 4 filing. |
| April 24, 2025 | Expiration date of the non-qualified stock option. |
Keywords
Form 4, Ligand Pharmaceuticals, Director, Stephen Sabba, Stock Options, Share Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.